Johnson & Johnson said Wednesday it expects to sell $2.5 billion of its Covid-19 vaccine, even as concerns mount over the shot’s effectiveness against the delta variant.
In releasing its second-quarter financial results, the company also reported earnings and revenue that beat Wall Street’s expectations.
Here’s how J&J did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:
- Adjusted EPS: $2.48 per share vs $2.27 expected.
- Revenue: $23.31 billion vs $22.21 billion expected.
The company’s share price was up nearly 1% in premarket trading following the report.
This is a developing story. Please check back for updates.